Neximmune Inc (NEXI) Took The Aerial Rout In The Pre-Market Session

In a surprising twist, Neximmune Inc (NEXI) has shown an exceptional performance during the pre-market hours today, creating ripples in the financial realm. The stock experienced a remarkable surge of 208.21%, or $4.95 in this early trading session. Notably, the trading volume in the pre-market soared to a substantial 8.31 million shares, signaling a surge in investor engagement and increased market dynamics.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The substantial shift in Neximmune’s pre-market activity sparks curiosity, prompting a closer look at the underlying factors behind this impressive stock value change. Market participants are closely monitoring the consequences of this significant pre-market upswing as the trading day unfolds.

Latest News

On October 24, 2023, NexImmune, Inc. (Nasdaq: NEXI) disclosed the expansion of the collaborative research initiative involving NexImmune, Yale, and JDRF, aimed at exploring the application of NexImmune’s AIM nanoparticles in conjunction with an anti-CD3 mAb to tolerize, deplete, or modulating diabetes antigen-specific T cells.

As part of the extension, JDRF has allocated an additional grant of $300,000 to Yale under its Cures research portfolio, focusing on therapies for type 1 diabetes (T1D) prevention.

The JDRF grant will continue supporting investigations into using NexImmune’s AIM nanoparticles in combination with a murine surrogate of teplizumab, known to modulate the pathogenic immune response acutely.

The integration of anti-CD3 treatment with NexImmune’s injectable therapy presents an opportunity to specifically target and modulate T1D antigen-specific T cells, potentially sustaining their non-responsiveness to extend benefits and induce tolerance. The unique properties of NexImmune’s nanoparticles offer the potential to further amplify the impact of anti-CD3 by influencing the residual T1D-specific T cells.


Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular